Skip to main content
SpringerLink
Log in

Oral Administration of Avian Tumor Necrosis Factor Antibodies Effectively Treats Experimental Colitis in Rats

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF) is implicated in the pathogenesis of inflammatory bowel disease. Clinical trials indicate that intravenous infusion of anti-TNF antibody is an effective therapy for Crohn's disease. An oral anti-TNF therapy may be a preferred approach, reducing systemic side effects and eliminating the inconvenience and expense of administering infusions. We tested oral avian anti-TNF antibodies in the acute and chronic phases of a rodent colitis model. Efficacy was compared to sulfasalazine and dexamethsone. Rats with chemically induced colitis were treated orally with anti-TNF antibody, placebo, or comparator. Efficacy was assessed by change in colonic weight, morphology, histology, and tissue myeloperoxidase activity. Oral anti-TNF antibody, in both the acute and chronic phases of the model, significantly decreased all inflammatory end points and proved to be more effective than sulfasalazine and dexamethasone. Oral delivery of avian anti-TNF antibodies is an effective treatment of experimental colitis and may provide advantages to current parenteral anti-TNF antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Hay A, Hay J: Inflammatory bowel disease. Cost of illness. J Clin Gastroenterol 14:309-317, 1992

    Google Scholar 

  2. Hanauer SB: Inflammatory bowel disease. N Engl J Med 331:841-848, 1996

    Google Scholar 

  3. Papadakis KA, Targan SR: Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am 28:283-296, 1999

    Google Scholar 

  4. Zhang M, Tracy KJ: Tumor necrosis factor. In The Cytokine Handbook, 3rd ed. A Thomson (ed). San Diego, Academic Press, 1998, pp 517-548

    Google Scholar 

  5. Hawkey CJ: Inflammatory mediators. In Inflammatory Bowel Diseases. RN Allan, JM Rhodes, SB Hanauer (eds). New York, Churchill Livingstone, 1997, pp 521-534

    Google Scholar 

  6. Tracy KJ: Tumor necrosis factors. In Cytokines in Health and Disease. DG Remick, JS Friedland (eds). New York, Marcel Dekker, 1997, pp 223-239

    Google Scholar 

  7. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337:1029-1035, 1997

    Google Scholar 

  8. Rutgeerts PJ, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769, 1999

    Google Scholar 

  9. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5:119-133, 1999

    Google Scholar 

  10. Nicholls S, Stephens S, Bragger CP, Walker-Smith JA, Mac-Donald TT: Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 46:757-760, 1993

    Google Scholar 

  11. Poulson A, von Wechmar BM, Fazakerley G: Antibodies to proteins from yolk of immunized hens. Immunol Commun 9:495-514, 1980

    Google Scholar 

  12. Kink JA, Williams JA: Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018-2025, 1998

    Google Scholar 

  13. Hogan MM, Vogel SN: Production of TNF by rIFN-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid-A-associated proteins. J Immunol 141:4196-4202, 1988

    Google Scholar 

  14. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989

    Google Scholar 

  15. Sartor RB: How relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment Pharmacol Ther 11(suppl 3):89-97, 1997

    Google Scholar 

  16. Zingarelli B, Squadrito F, Granziani P, Camerini R, Caputi AP: Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 39:150-156, 1993

    Google Scholar 

  17. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR: Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 157:2174-2185, 1996

    Google Scholar 

  18. Krawisz JE, Sharon P, Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87:1344-1350, 1984

    Google Scholar 

  19. Murch SH, Braegger CP, Walker SJ, Mac DT: Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory disease. Gut 34:1705-1709, 1993

    Google Scholar 

  20. Elson CO, Sartor RB, Tennyson GS, Riddel RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367, 1995

    Google Scholar 

  21. Zhang XM, Weber I, Chen MJ: Site-directed mutational analysis of human tumor necrosis factor-areceptor binding site and structure function relationship. J Biol Chem 267:24069-24075, 1992

    Google Scholar 

  22. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies. Clin Diagnostic Lab Immunol 1:365-372, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophidian Pharmaceuticals, Inc., Madison, Wisconsin

    Katherine L. Worledge, Ronald Godiska, Terrence A. Barrett & John A. Kink

  2. Department of Medicine and Microbiology/Immunology, Northwestern University Medical School, Chicago, Illinois

    Katherine L. Worledge, Ronald Godiska, Terrence A. Barrett & John A. Kink

Authors
  1. Katherine L. Worledge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald Godiska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terrence A. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John A. Kink
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Worledge, K.L., Godiska, R., Barrett, T.A. et al. Oral Administration of Avian Tumor Necrosis Factor Antibodies Effectively Treats Experimental Colitis in Rats. Dig Dis Sci 45, 2298–2305 (2000). https://doi.org/10.1023/A:1005554900286

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005554900286

Search

Navigation